Table 5.
Hazard ratios of ESRD associated with APOL1 risk allele
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Hazard Ratio | P Value | Hazard Ratio | P Value | |
| (95% CI) | (95% CI) | |||
| APOL1, 2 versus 0/1 risk alleles | 1.98 (0.93–4.24) | 0.08 | 2.86 (1.12–7.32) | 0.03 |
| Age, per year increase | 0.97 (0.29–1.02) | 0.29 | 0.98 (0.93–1.04) | 0.50 |
| Female | 0.79 (0.33–1.85) | 0.59 | — | — |
| Hepatitis C antibody seropositivity | 1.02 (0.49–2.12) | 0.96 | 1.14 (0.44–2.91) | 0.79 |
| Diabetic | 1.38 (0.47–4.02) | 0.56 | 0.79 (0.17–3.60) | 0.76 |
| Hypertensive | 0.78 (0.37–1.63) | 0.50 | 0.66 (0.27–1.65) | 0.37 |
| HIV-1 RNA level, per log10 1 copy/ml higher | 1.28 (0.94–1.74) | 0.36 | 1.21 (0.76–1.94) | 0.42 |
| CD4+cell count, per 1 cell/mm3 higher | 1.00 (0.99–1.00) | 0.10 | 1.00 (0.99–1.00) | 0.92 |
| Baseline eGFR, per log10-1 ml/min per 1.73 m2 lower | 10.47 (2.87–38.15) | <0.001 | 10.48 (1.79–61.27) | 0.009 |
| Proteinuric at baseline | 5.94 (0.80–43.94) | 0.08 | 3.63 (0.46–28.54) | 0.22 |
Proteinuria defined as spot urine protein/creatinine ratio >200 mg/g. eGFR, estimated GFR.